论文部分内容阅读
目的探讨急性冠脉综合征（ACS ）患者早期应用瑞舒伐他汀对血脂及血清超敏C反应蛋白（hs‐CRP）、白介素‐6（IL‐6）的影响。方法采用随机分组病例对照研究，选择本院临床确诊为ACS的54例患者随机分为常规治疗组（A组，n＝26）、瑞舒伐他汀治疗组（B组，n＝28），另选20名同期本院体检中心体检正常者作为对照（C组，n＝20），B组患者在ACS确诊的24～48 h内在常规治疗基础上给予瑞舒伐他汀5～10 mg ，每晚1次，治疗8周，采用双抗体夹心酶联吸附法（ELISA ）测定两组患者治疗前后血清IL‐6，免疫散射比浊法检测hs‐CRP。结果治疗前ACS患者血脂、IL‐6、hs‐CRP水平较C组显著升高（ P＜0．01），A、B两组患者之间血脂、IL‐6、hs‐CRP无显著性差异（ P ＞0．05）；治疗后，B组患者低密度脂蛋白胆固醇（LDL‐C）、IL‐6、hs‐CRP显著下降（ P＜0．05），与A组比较，有显著性差异（ P ＜0．05）。结论 ACS患者存在炎症反应，早期应用瑞舒伐他汀能够改善患者的炎症状态，减少心血管事件。“,”[Objective]To explore the effect of early use of rosuvastatin on blood lipids and inflammatory factors high sensitive C‐reactive protein(hs‐CRP) and interleukin‐6(IL‐6) in patients with acute coronary syndrome(ACS) .[Meth‐ods]A total of 54 patients confirmed as ACS by clinical diagnosis in our hospital were chosen and randomly divided into routine treatment group(group A ,n=26) and rosuvastatin treatment group(group B ,n =28) by using randomization case control method .Other 20 concurrent healthy subjects were chosen as the control group(group C ,n=20) .Patients in group B were given rosuvastatin(crestor produced by astrazeneca company) 5~10mg within 24~28h after the diagnosis of ACS once per night based on routine treatment .The course was 8 weeks .Double antibody sandwich enzyme‐linked im‐munosorbent assay(ELISA) was used to detect serum IL‐6 of patients in two groups before and after treatment ,and im‐muno‐turbidimetry was used to determine hs‐CRP .[Results]Compared with group C ,blood lipids ,IL‐6 and hs‐CRP in ACS patients before treatment increased significantly( P0 .05) .Low density lipoprotein cholesterol(LDL‐C) ,IL‐6 and hs‐CRP in group B after treatment de‐creased significantly( P<0 .05) ,and there was significant different between group B and group A( P<0 .05) .[Conclu‐sion]ACS patients have inflammatory response .Early use of rosuvastatin can improve inflammatory status and reduce car‐diovascular events of patients .